Secukinumab lowers expression of ACE2 in affected skin of patients with psoriasis

Krueger, James G.; Murrell, Dédée F.; Garcet, Sandra; Navrazhina, Kristina; Lee, Patricia C.; Muscianisi, Elisa; Blauvelt, Andrew

doi:10.1016/j.jaci.2020.09.021

Cited by 21 publications

(22 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Conversely, interclass switching from IFX to IL‐17 blockers is motivated by the administration (intravenous vs. subcutaneous), the faster response, longer drug survival, 28 the lower number of administrations, the decreased drug immunogenicity, 26 the effect in ACE2 receptor utilized by SARS‐CoV‐2 8 and the evidence regarding COVID‐19 vaccination in PsO patients. 5 …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Switching infliximab in psoriatic patients during COVID ‐19 pandemics: A real‐life retrospective study comparing intra‐versus interclass switching strategies

Conti

Damiani

Ruggeri

et al. 2021

Dermatologic Therapy

View full text Add to dashboard Cite

During this pandemic, dermatological infusion centers were partially unavailable, suspended or even reconverted to guest COVID‐19 patients, consequently infliximab (IFX) infusions became challenging for their both logistic arrangement and also for patients' COVID‐19 phobia. This 48 weeks follow‐up retrospective observational study included 37 PsO patients that underwent IFX SB2 during pandemic in two primary dermatological referral centers. In 23 (62.1%) we had to switch from IFX to other biologics, not motivated by adverse reactions, contraindication or even loss of response but only to pandemic related conditions. Nine patients underwent interclass switching and 15 underwent intraclass switching; interestingly 2 patients that underwent adalimumab SB‐5 switched back to IFX. Interclass switching was privileged in elder patients and smokers. All patients at week 48 achieved PASI 100. Intra‐ and interclass switchings are both safe and effective strategies in psoriatic patients with COVID‐19 phobia and/or difficulties to undergo infliximab infusions.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Thus, several IFX responders asked to switch to another anti‐psoriatic biologic drug and, at the moment, no indications are present to orient intraclass or interclass switchings. 8 , 9 , 10 …”

Section: Introductionmentioning

confidence: 99%

Switching infliximab in psoriatic patients during COVID ‐19 pandemics: A real‐life retrospective study comparing intra‐versus interclass switching strategies

Conti

Damiani

Ruggeri

et al. 2021

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…Sun et al ( 65 ) found that the co-expression of ACE2 and TMPRSS2 was particularly found in the granulosum of skin, so they proposed the hypothesis that skin is a potential host of SARS-CoV-2 and there is a potential risk of SARS-CoV-2 transmission via wounded skin in those with skin manifestations of the disease. Controlled studies on patients with psoriasis have shown a significantly increased expression of ACE2 ( p = 0.009) in lesion skin compared with healthy controlled skin, but no significant difference was observed for TMPRSS2 ( p = 0.19) ( 63 , 66 ). These findings suggest that whether the skin lesions of patients with psoriasis are the target of SARS-CoV-2 infection still needs further investigation.…”

Section: The Relationship Between Psoriasis and Covid-19mentioning

confidence: 94%

Biologics for Psoriasis During the COVID-19 Pandemic

et al. 2021

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19), a new form of acute infectious respiratory syndrome first reported in 2019, has rapidly spread worldwide and has been recognized as a pandemic by the WHO. It raised widespread concern about the treatment of psoriasis in this COVID-19 pandemic era, especially on the biologics use for patients with psoriasis. This review will summarize key information that is currently known about the relationship between psoriasis, biological treatments, and COVID-19, and vaccination-related issues. We also provide references for dermatologists and patients when they need to make clinical decisions. Currently, there is no consensus on whether biological agents increase the risk of coronavirus infection; however, current research shows that biological agents have no adverse effects on the prognosis of patients with COVID-19 with psoriasis. In short, it is not recommended to stop biological treatment in patients with psoriasis to prevent the infection risk, and for those patients who tested positive for SARS-CoV-2, the decision to pause biologic therapy should be considered on a case-by-case basis, and individual risk and benefit should be taken into account. Vaccine immunization against SARS-CoV-2 is strictly recommendable in patients with psoriasis without discontinuation of their biologics but evaluating the risk-benefit ratio of maintaining biologics before vaccination is mandatory at the moment.

show abstract

“…However, psoriasis, a skin disease with a prevalence that increases with advancing age [ 403 ], also showed a significant promoting effect on the expression of ACE2 in skin, which rendered the patients more prone to SARS-CoV-2 infection [ 404 ]. However, biological therapy using secukinumab lowered the expression of ACE2 in the skin of psoriasic patients [ 405 ]. Furthermore, a higher expression of ACE2 - and related genes has been observed in the skin samples of patients with atopic dermatitis [ 406 ].…”

Section: Cellular Aging Of Skin and Covid-19 Pandemicmentioning

confidence: 99%

Skin Aging, Cellular Senescence and Natural Polyphenols

Csekes

Račková

2021

IJMS

126

View full text Add to dashboard Cite

The skin, being the barrier organ of the body, is constitutively exposed to various stimuli impacting its morphology and function. Senescent cells have been found to accumulate with age and may contribute to age-related skin changes and pathologies. Natural polyphenols exert many health benefits, including ameliorative effects on skin aging. By affecting molecular pathways of senescence, polyphenols are able to prevent or delay the senescence formation and, consequently, avoid or ameliorate aging and age-associated pathologies of the skin. This review aims to provide an overview of the current state of knowledge in skin aging and cellular senescence, and to summarize the recent in vitro studies related to the anti-senescent mechanisms of natural polyphenols carried out on keratinocytes, melanocytes and fibroblasts. Aged skin in the context of the COVID-19 pandemic will be also discussed.

show abstract

Secukinumab lowers expression of ACE2 in affected skin of patients with psoriasis

Cited by 21 publications

References 11 publications

Switching infliximab in psoriatic patients during COVID ‐19 pandemics: A real‐life retrospective study comparing intra‐versus interclass switching strategies

Switching infliximab in psoriatic patients during COVID ‐19 pandemics: A real‐life retrospective study comparing intra‐versus interclass switching strategies

Biologics for Psoriasis During the COVID-19 Pandemic

Skin Aging, Cellular Senescence and Natural Polyphenols

Contact Info

Product

Resources

About